Drug Profile
ALECSAT - CytoVac
Alternative Names: ALECSATLatest Information Update: 23 Jul 2022
Price :
$50
*
At a glance
- Originator CytoVac
- Class Cell therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Immunostimulants; Natural killer cell replacements; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Glioblastoma; Sarcoma
- Phase I/II Triple negative breast cancer
- Phase I Pancreatic cancer; Prostate cancer
Most Recent Events
- 23 Jul 2022 Phase I/II development in Triple-negative-breast cancer (Metastatic disease, Adjunctive treatment, Late-stage disease) is ongoing in Denmark (IV) (NCT04609215) (EudraCT2019-001420-34)
- 13 Jun 2022 ALECSAT is still in phase I trials for pancreatic cancer and prostate cancer in Denmark (CytoVac pipeline, June 2022)
- 13 Jun 2022 ALECSAT - CytoVac is available for licensing for pancreatic cancer and prostate cancer as of 13 Jun 2022 (https://cytovac.com/pipeline-clinical-data/pipeline/)